Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ASKG915 + Docetaxel |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ASKG915 | ASKG 915|ASKG-915 | PD-L1/PD-1 antibody 136 | ASKG915 is an anti-PD-1/IL-15 prodrug fusion molecule that potentially induces antitumor immune activity (J Immunother Cancer 2022;10(Suppl 2):1183). | |
| Docetaxel | Taxotere | RP56976 | Antimicrotubule Agent 14 | Taxotere (docetaxel) binds to tubulin, inhibiting microtubule disassembly and preventing cell division (PMID: 32496783, PMID: 32366558). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05867420 | Phase Ib/II | ASKG915 + Fruquintinib ASKG915 ASKG915 + Bevacizumab + Paclitaxel ASKG915 + Docetaxel | A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. | Recruiting | USA | 1 |